Life Biosciences reports Phase 1 ER-100 data in glaucoma
Life Biosciences has released interim data from its ongoing Phase 1 trial of ER-100 in optic neuropathies, marking the first time the company's epigenetic restoration approach has been evaluated in human participants. The Boston-based biotech reported that a single intravitreal injection of ER-100, given alongside eight weeks of daily oral doxycycline to induce expression of the OSK transcription factor trio, was well-tolerated through Day 56 in all three participants with open-angle glaucoma.
No dose-limiting toxicities, serious adverse events or adverse events of special interest were reported. Adverse events that did occur were attributed to the administration procedure, steroid use or pre-existing conditions rather than to ER-100 directly. The Data Safety Monitoring Board reviewed the Dose Level 1 data and recommended progression to Dose Level 2, at a viral vector dose of 6x10^11 vg compared with the 2x10^11 vg used at Dose Level 1.
Preliminary efficacy signals
Beyond tolerability, the company highlighted visual field observations in two of the three participants. Using Humphrey Visual Field testing, a standard ophthalmic assessment measuring light-detection sensitivity across the visual field in decibels, both participants showed a greater than 4 dB improvement in at least 28% of measured points at Day 56. Life Biosciences was careful to frame these as preliminary signals rather than evidence of efficacy, and the trial is designed principally to assess safety and tolerability.
Sharon Rosenzweig-Lipson, Chief Scientific Officer at Life Biosciences, said the visual field observations were "encouraging" while noting that the primary aim of the study remains characterising the safety profile. She described the Data Safety Monitoring Board's escalation recommendation as allowing the company to keep "moving this trial forward on behalf of people living with optic neuropathies like glaucoma, a disease where vision loss is often considered irreversible."
Market and competitive context
Optic neuropathies present a significant unmet need. Open-angle glaucoma is one of the leading causes of blindness globally, and disease progression frequently continues in a subset of patients despite pressure-lowering treatments. Non-arteritic anterior ischemic optic neuropathy, the other indication ER-100 is targeting, has no approved treatment at all.
The broader epigenetic reprogramming field has attracted substantial scientific and investor attention, with a number of companies and academic groups pursuing OSK-based or partial reprogramming approaches in ageing-related tissue damage. Life Biosciences is among the first to present human data using this mechanism in the eye, where the retinal ganglion cells targeted by ER-100 are known not to regenerate naturally after injury. The use of an AAV-2 vector delivered intravitreally is an established route for ocular gene therapy, offering regulatory and manufacturing precedent, though immune responses to AAV vectors remain a monitored risk, hence the oral prednisolone taper included in the protocol.
The trial, registered as NCT07290244, is ongoing. Investors and clinicians will be watching for Dose Level 2 tolerability data, longer-term follow-up on visual endpoints beyond Day 56, and any signals in the NAION cohort as the study broadens. With the field of cellular rejuvenation medicines still largely in early clinical development, each human dataset carries outsized significance for the platform's credibility.